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The IL-33-ST2L Pathway Is Associated
with Coronary Artery Disease
in a Chinese Han Population
Xin Tu,1,12 Shaofang Nie,2,12 Yuhua Liao,2,12 Hongsong Zhang,2,12 Qian Fan,2 Chengqi Xu,1 Ying Bai,1
Fan Wang,3 Xiang Ren,1 Tingting Tang,2 Ni Xia,2 Sisi Li,1 Yuan Huang,1 Juan Liu,2 Qing Yang,1
Yuanyuan Zhao,1 Qiulun Lv,1 Qingxian Li,4 Yue Li,5 Yunlong Xia,6 Jin Qian,7 Bin Li,8 Gang Wu,9
Yanxia Wu,10 Yan Yang,11 Qing K. Wang,1,* and Xiang Cheng2,*
The effects of interleukin-33 (IL-33) on the immune system have been clearly demonstrated; however, in cardiovascular diseases,
especially in coronary artery disease (CAD), these effects have not yet been clarified. In this study, we investigate the genetic role of
the IL-33-ST2L pathway in CAD. We performed three-stage case-control association analyses on a total of 4,521 individuals with
CAD and 4,809 controls via tag SNPs in the genes encoding IL-33 and ST2L-IL-1RL1. One tag SNP in each gene was significantly
associated with CAD (rs7025417T in IL33, padj ¼ 1.19 3 1028, OR ¼ 1.39, 95% CI: 1.31–1.47; rs11685424G in IL1RL1, padj ¼ 6.93 3
1030, OR ¼ 1.40, 95% CI: 1.32–1.48). Combining significant variants in two genes, the risk for CAD increased nearly 5-fold
(padj ¼ 8.90 3 1021, OR ¼ 4.98, 95% CI: 3.56–6.97). Traditional risk factors for CAD were adjusted for the association studies by
SPSS with logistic regression analysis.With the two variants above, both locatedwithin the gene promoter regions, reporter gene analysis
indicated that the rs7025417 C>T and rs11685424 A>G changes resulted in altered regulation of IL33 and IL1RL1 gene expression,
respectively (p < 0.005). Further studies revealed that the rs7025417 genotype was significantly associated with plasma IL-33 levels
in the detectable subjects (n ¼ 227, R2 ¼ 0.276, p ¼ 1.77 3 1017): the level of IL-33 protein increased with the number of
rs7025417 risk (T) alleles. Based on genetic evidence in humans, the IL-33-ST2L pathway appears to have a causal role in the
development of CAD, highlighting this pathway as a valuable target for the prevention and treatment of CAD.Introduction
Coronary artery disease (CAD [MIM 608320, 610947,
611139, 608901, 607339, 608316]), a complex trait that
results from multiple genetic and environmental factors
and their interactions, is the leading cause of morbidity
and mortality worldwide.1,2 In 2002 and 2007, Zdravkovic
et al. estimated that the total heritability of CAD was 0.57
inmen and 0.38 in women for death3 and 0.39 inmen and
0.43 in women for angina, based on a longitudinal study of
more than 20,000 Swedish twins.4 Recently, large-scale
genome-wide association studies (GWASs) have identified
approximately 50 risk loci for CAD.5–15 However, these
risk loci primarily have modest effect sizes (odds ratios ¼
1.04–1.28) and collectively explain only approximately
10.6% of the total CAD heritability.15–17 Therefore, a large
proportion of the heritability of CAD remains unexplained
and is called ‘‘missing heritability.’’17
Inflammation has been demonstrated to play a key role
in the pathogenesis of atherosclerotic CAD.18 Consider-
able evidence from animal studies has indicated that
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observed that variants in the genes encoding interleukin-1
receptor antagonist, IL-6, IL-10, IL-16, IL-17A, and
IL-18 are also genetically associated with atherosclerosis
and CAD.20–24
Recently, it was confirmed that the novel cytokine IL-33,
a member of the IL-1 family, and its receptor ST2L-IL-
1RL1 play important roles in inflammatory diseases.
Furthermore, Miller et al. demonstrated that the IL-
33-ST2L pathway might inhibit the development of
atherosclerosis.25 Therefore, we speculated that the IL-33-
ST2L pathway might be genetically associated with CAD.
To confirm this possibility, we performed the following
steps: (1) a case-control association study for CAD based
on the GeneID Chinese Han population, by using tag
SNPs covering IL33 (MIM 608678) and IL1RL1 (MIM
601203) with a large discovery sample size; (2) an inter-
action analysis between the most significant variants of
IL33 and IL1RL1 in the association with CAD; (3) a reporter
gene assay to investigate the function of the reference
variants; and (4) a circulation level study of IL-33 in the
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Figure 1. LD Blocks of IL33 and IL1RL1 Based on the HapMap CHB and JPT Data Sets
LD blocks of (A) IL33 and (B) IL1RL1 are shown. The arrows indicate the selected tag SNPs. Each diamond represents the LD degree
between the SNPs. The color indicates the D0 (a redder color represents a higher D0) and the numbers within the diamonds are the r2
values (r2 > 0.55 and D0 > 0.83 in the blocks of both genes).Material and Methods
Study Population
The GeneID Chinese Han population is an ongoing database that
was established for studying the genetic basis of various cardiovas-
cular diseases.13,26–28 The study subjects were 4,521 CAD cases and
4,809 controls, who were acquired from this database in three
stages: first, the discovery population of 860 cases and 707 con-
trols was assembled from eastern China; second, the validation
population of 575 cases and 471 controls was assembled from
northern China; and third, two replication populations with
much larger sample sizes (2,016 cases and 1,647 controls in repli-
cation 1 and 1,070 cases and 1,984 controls in replication 2) were
assembled from central China.
The criterion for the enrolment as a CAD case was >70%
luminal stenosis in at least one main vessel, as identified by coro-
nary angiography, coronary artery bypass graft, percutaneous
coronary intervention, and/or myocardial infarction. Individuals
were excluded from the study if they had experienced myocardial
spasms or had a myocardial bridge, as identified by angiography,
or had congenital heart disease, childhood hypertension, or
type 1 diabetes mellitus.
The control subjects in the discovery and validation studies
were defined as individuals without atherosclerotic lesions, as
confirmed by angiography, and without any history of CAD. In
the large replication studies, the control subjects were selected
from the general population among individuals undergoing
physical examinations. Study subjects who had notes of potential
CAD or myocardial infarction in their medical records or from
electrocardiographic tests were excluded.
The disease status of hypertension and diabetes mellitus were
evaluated, and the lipid profile (total cholesterol [Tch], low-density
lipoprotein cholesterol [LDL-c], high-density lipoprotein choles-
terol [HDL-c], and triglyceride [TG]) was measured according to
guidelines and standard methods.29–31 Other clinical data, suchThe Americas age, gender, body mass index (BMI), and smoking history,
were obtained via direct interviews or a medical records review.
The study complied with the ethical principles set forth by the
Declaration of Helsinki, and approval was obtained from the local
institution review boards on human subject research. Informed
consents were obtained from all of the participants.
Genetic Analysis
The DNA samples were collected from peripheral blood. Tag SNPs
were selected according to the following principles: (1) linkage
disequilibrium (LD) between SNPs according to Haploview
(v.4.2) based on HapMap CHB and JPT data sets (v.3, release 2)
with the thresholds of r2 > 0.4 and D0 > 0.7 to reduce the
redundancy;32,33 (2) potential functional sites predicted by bioin-
formatics (Promoter and Genevar); and (3) a minor allele fre-
quency (MAF) threshold of greater than 0.05. Data were excluded
if the allele call rate was less than 95% or the Hardy-Weinberg
equilibrium (HWE) c2 p value was less than 0.001. The selected
tag SNPs were rs7025417, rs10975514, and rs10975519 in IL33
and rs11685424 and rs3771180 in IL1RL1 (Figure 1). rs7025417
and rs11685424 were located in the predicted promoter regions,
which might regulate the expression of the genes.
Genotyping was performed with a Roto-gene 6000 High-
Resolution Melt (HRM) system (Corbett Life Science),26–28 with a
total of 25 ml PCR volume containing 1 ml of LC Green dye, 5
pmol of each primer, 25 ng of genomic DNA, 2.5 ml of 103 PCR
buffer with 1.5 mmol/l MgCl2, 5 mmol deoxynucleotide triphos-
phates, and 1 unit of Taq polymerase. Two positive controls for
each genotype were included in each run, and the data with call
rates of less than 95% were excluded. For each SNP, a total of 48
cases and controls were randomly selected for the verification of
genotyping results by direct DNA sequencing analysis. DNA
sequence analysis was performed with forward and/or reverse
primers with the BigDye Terminator v3.1 Cycle Sequencing Kits
on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).an Journal of Human Genetics 93, 652–660, October 3, 2013 653
Reporter Gene Assay
Because rs7025417 and rs11685424 were both located in the pro-
moter region, which could influence gene expression, we con-
ducted a reporter gene assay.34 We first subcloned a 1,556 bp
50 UTR sequence of IL33 containing the rs7025417 C allele into
a pGL3 basic vector (Promega Corporation). After confirmation
by restriction mapping and direct sequencing, the pGL3 vector
containing the ‘‘C’’ allele of rs7025417 was used as a template
to generate the insert containing the T allele by using a site-
directed mutagenesis kit (Promega). Direct sequencing was used
to verify the two plasmids (IL33-C and IL33-T). The human
lung adenocarcinoma cell line A549 and the human embryonic
kidney cell line 293 (HEK293) (American Type Culture Collection
[ATCC]) were transfected with 500 ng of each plasmid simul-
taneously with 50 ng of a pRL-TK vector (Promega) using
Lipofectamine 2000 (Invitrogen). After 48 hr, firefly luciferase
activity was measured with a Dual Luciferase Reporter Assay Kit
(Promega). Three independent experiments were conducted,
and each was performed in triplicate. The empty pGL3-basic
vector was used as the negative control.
For IL1RL1, the constructed plasmids contained the rs11685424
A or G allele and the distal promoter sequence, totaling 1,218 bp
continuous with exon 1a of IL1RL1. The two plasmids carrying
IL1RL1 (IL1RL1-A and IL1RL1-G) were transfected into the human
mast cell line CHMAS (ATCC) by nucleofection (Amaxa Cell Line
Nucleofector Kit R).Circulation Level Test for IL-33
Blood samples for the determination of IL-33 were collected in
tubes containing potassium EDTA at the time that the subjects
enrolled in the GeneID Chinese Han Population database. After
centrifugation, plasma samples were frozen at 80C for less
than 2 months. The concentrations of IL-33 were measured in
440 individuals with CAD by enzyme-linked immunosorbent
assay (ELISA) with commercially available LEGEND MAX kits
(BioLegend). The detection sensitivity was 4.14 pg/ml.Statistical Analyses
Hardy-Weinberg disequilibrium tests were performed among con-
trols for each population by PLINK. The allelic and genotypic
associations for each SNP were analyzed by Pearson’s 2 3 2 and
2 3 3 contingency table chi-square tests, and the odds ratio
(OR) and 95% confidence interval (CI) were also calculated.
Traditional risk factors for CAD, including age, gender, BMI,
hypertension, diabetes mellitus, smoking history, Tch, HDL-c,
LDL-c, and TG, were analyzed as covariates by multiple logistic
regression models. Testing for interactions used logistic regression
analysis under the genotypic model as suggested.35 Statistical
power analysis and sample size estimation for validation and
replication populations were performed with a free power and
sample size calculation program (PS v.3.0.12) for single-variant
association analysis and a free software program, QANTO, for
interaction analysis (QANTO v.1.2.4). The luciferase activity
difference was tested with Student’s t test (independent samples
test, four degrees of freedom), and statistical significance was
defined as a p value of less than 0.05. Analysis of association
between the rs7025417 genotypes and IL-33 plasma concentra-
tions was performed with a linear regression model, assuming
an additive effect of the allele. The Mann-Whitney U test was
used to test for differences in the IL-33 levels in the subjects
with different genotypes of rs7025417.654 The American Journal of Human Genetics 93, 652–660, OctoberResults
Population Characteristics
Table 1 illustrates the detailed clinical features of the three
cohorts. The age, gender, and BMI did not differ between
the case subjects and control subjects; the LDL-c, smoking,
hypertension, and diabetes mellitus were significantly
different. The case individuals had higher levels of LDL-c
and a higher incidence of smoking, hypertension, and
diabetes mellitus than those of the controls in all four
populations.
Under the population parameter settings of the effect
size (OR ¼ 1.2 for CAD),28 the allele frequency of 0.46
(HapMap CHB and JPT data sets, the minimum minor
allele frequency for rs11685424 between the two signifi-
cant variants in the discovery study), our sample size
provides a statistical power of 60% in the validation popu-
lation, 97.3% in the replication 1 population, and 92.4%
in the replication 2 population.
The prior statistical power used to detect the interaction
between rs7025417 in IL33 and rs11685424 in IL1RL1
under the genotypic model for their association with
CAD was greater than 80% in the combined population.
Association Analysis of Single Variants with CAD
in the GeneID Chinese Han Population
There was no deviation from the Hardy-Weinberg equilib-
rium for all of the SNPs in the control subjects. In the
GeneID-discovery population, both IL33 and IL1RL1
possessed a promoter variant that was significantly associ-
ated with CAD (rs7025417T in IL33, padj ¼ 1.38 3 104,
OR ¼ 1.32, 95% CI: 1.14–1.52; rs11685424G in IL1RL1,
padj ¼ 2.12 3 103, OR ¼ 1.25, 95% CI: 1.08–1.44). In the
GeneID-validation population, the SNPs rs7025417 and
rs11685424 were also significantly associated with CAD
(rs7025417T in IL33, padj ¼ 7.69 3 106, OR ¼ 1.49, 95%
CI: 1.25–1.77; rs11685424G in IL1RL1, padj ¼ 1.25 3 104,
OR¼ 1.40, 95%CI: 1.18–1.67). In the large GeneID-replica-
tion1population, theassociationsbetween the twovariants
and CAD were still significant (rs7025417T in IL33, padj ¼
2.32 3 107, OR ¼ 1.28, 95% CI: 1.16–1.40; rs11685424G
in IL1RL1, padj ¼ 1.15 3 1012, OR ¼ 1.40, 95% CI: 1.28–
1.53). In the GeneID-replication 2 population, the associa-
tions between the two variants and CAD was confirmed
(rs7025417T in IL33, padj ¼ 1.06 3 1012, OR ¼ 1.47, 95%
CI: 1.33–1.66; rs11685424G in IL1RL1, padj¼ 2.173 1013,
OR¼ 1.49, 95% CI: 1.34–1.65) (Table 2). In addition, geno-
typic association analysis also demonstrated that rs7025417
in IL33 and rs11685424 in IL1RL1were significantly associ-
atedwithCADinall threepopulation stages, aswell as in the
combined population (Table S1 available online).
rs10975514 and rs10975519 in IL33 and rs3771180 in
IL1RL1, which failed to show significant associations
with CAD in the GeneID-discovery population (the lowest
adjusted p value of the three SNPs is 0.20 for rs10975514)
(Table S2), were excluded from the next two stages of the
study.3, 2013
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The AmericAssociation Analysis of rs7025417 in IL33 and
rs11685424 in IL1RL1 with Subgroups of CAD
in the GeneID-Combined Population
We separated the individuals with CAD into two sub-
groups: GeneID-anatomical-CAD, n ¼ 1,598, individuals
with anatomical disease (severe coronary stenosis); and
GeneID-clinical-CAD, n ¼ 2,923, individuals with clinical
disease (myocardial infarction or revascularization). In
GeneID-anatomical-CAD, the associations between the
two SNPs and CAD were significant, with OR values of
more than 1.3 for both (rs7025417T in IL33, padj ¼
3.79 3 1011, OR ¼ 1.32, 95% CI: 1.22–1.44;
rs11685424G in IL1RL1, padj ¼ 2.73 3 1013, OR ¼ 1.36,
95% CI: 1.25–1.48). In GeneID-clinical-CAD, the associa-
tions of the two SNPs with myocardial infarction or revas-
cularization were also significant, with OR values of
approximately 1.4 for both variants (rs7025417T in IL33,
padj ¼ 8.57 3 1022, OR ¼ 1.39, 95% CI: 1.30–1.49;
rs11685424G in IL1RL1, padj ¼ 9.48 3 1022, OR ¼ 1.39,
95% CI: 1.30–1.49) (Table 2). Genotypic association anal-
ysis also demonstrated that the two SNPs were significantly
associated with CAD in both subgroups (Table S1).
Interaction Analysis between rs7025417 in IL33 and
rs11685424 in IL1RL1 under the Genotypic Model
in the GeneID-Combined Population
Because the sample size in the GeneID-combined popula-
tion was sufficiently large to provide valuable statistical
power, we performed an interaction analysis between
rs7025417 in IL33 and rs11685424 in IL1RL1 under the
genotypic model in the combined population. The interac-
tion of the two SNPs (rs7025417 in IL33 and rs11685424 in
IL1RL1) in the association with CAD was highly signifi-
cant, with a p value of 2.81 3 1032 under the genotypic
model. Additionally, the combination with the largest
effect under the genotypic model was ‘‘TT/GG,’’ which
provided a nearly 5-fold increase in the risk for CAD
(padj ¼ 8.90 3 1021, OR ¼ 4.98, 95% CI: 3.56–6.97)
(Table 3, Figure 2A). Figure 2B directly illustrates that the
effect of the combination TT/GG was much stronger
than that of a single variant in the association with CAD.
Reporter Gene Analysis
Given that rs7025417 and rs11685424 were both located
within the gene promoter region and could therefore inter-
fere with the regulation of gene expression, we constructed
plasmids carrying IL33-C/T and IL1RL1-A/G. The assay was
performed in triplicate, and a representative result of the
three independent experiments is illustrated as the relative
luciferase activity in Figure 3. The luciferase activity in the
cells transfected with IL33-T plasmid was twice that in the
cells transfected with IL33-C plasmid, and the luciferase
activity in the cells transfected with the IL1RL1-G plasmid
was four times that in the cells transfected with the
IL1RL1-A plasmid (p < 0.005, Figure 3). These results indi-
cate that the rs7025417 C>T change may increase the
expression of IL33 and that the rs11685424 A>G changean Journal of Human Genetics 93, 652–660, October 3, 2013 655
Table 2. Allelic Association Analysis of rs7025417 in IL33 and rs11685424 in IL1RL1 with CAD in the GeneID Chinese Han Population
Population
n
Gene, SNP (Reference Allele)
Frequency
phwe pobs padj OR (95%CI)Cases Controls Case Control
GeneID Discovery 860 707 IL33, rs7025417T 0.585 0.516 0.259 1.02 3 104 1.38 3 104 1.32 (1.14–1.52)
IL1RL1, rs11685424G 0.567 0.515 0.293 3.63 3 103 2.12 3 103 1.25 (1.08–1.44)
GeneID Validation 575 471 IL33, rs7025417T 0.584 0.486 0.4 7.42 3 106 7.69 3 106 1.49 (1.25–1.77)
IL1RL1, rs11685424G 0.57 0.487 0.453 1.48 3 104 1.25 3 104 1.40 (1.18–1.67)
GeneID Replication 1 2,016 1,647 IL33, rs7025417T 0.589 0.528 0.008 2.28 3 107 2.32 3 107 1.28 (1.16–1.40)
IL1RL1, rs11685424G 0.566 0.483 0.776 1.08 3 1012 1.15 3 1012 1.40 (1.28–1.53)
GeneID Replication 2 1,070 1,984 IL33, rs7025417T 0.594 0.497 0.367 4.39 3 1013 1.06 3 1012 1.47 (1.33–1.66)
IL1RL1, rs11685424G 0.579 0.481 0.118 1.65 3 1013 2.17 3 1013 1.49 (1.34–1.65)
GeneID Combined 4,521 4,809 IL33, rs7025417T 0.591 0.509 0.001 1.41 3 1027 1.19 3 1028 1.39 (1.31–1.47)
IL1RL1, rs11685424G 0.573 0.487 0.027 6.25 3 1030 6.93 3 1030 1.40 (1.32–1.48)
GeneID Anatomical CAD 1,598 4,809 IL33, rs7025417T 0.579 0.509 0.001 6.06 3 1012 3.79 3 1011 1.32 (1.22–1.44)
IL1RL1, rs11685424G 0.565 0.487 0.027 2.37 3 1014 2.73 3 1013 1.36 (1.25–1.48)
GeneID Clinical CAD 2,923 4,809 IL33, rs7025417T 0.594 0.509 0.001 2.19 3 1024 8.57 3 1022 1.39 (1.30–1.49)
IL1RL1, rs11685424G 0.573 0.487 0.027 4.73 3 1025 9.48 3 1022 1.39 (1.30–1.49)
Abbreviations are as follows: phwe, p value from Hardy-Weinberg equilibrium tests; pobs, observed p value; padj, p value adjusted by covariates; OR, odds ratio after
adjustment.may increase the expression of IL1RL1. The results
exhibited for IL33 were tested in A549, and those for
IL1RL1 were tested in CHMAS. The results found in
HEK293 cells for IL33 were similar to those found in
A549 cells (data not shown).Association Analysis between the IL-33 Circulation
Level and rs7025417 Genotype
The detection rate of the plasma IL-33 concentration was
51.6% in the 440 individuals with CAD (median, 233.67Table 3. Interaction Analysis between rs7025417 in IL33 and
rs11685424 in IL1RL1 under the Genotypic Model in the GeneID
Combined Population
Types Case (%) Control (%) padj OR (95% CI)
TT/GG 675 (14.9) 416 (8.7) 8.90 3 1021 4.98 (3.56-6.97)
TT/GA 594 (13.1) 479 (10.0) 5.20 3 109 2.39 (1.78-3.20)
TT/AA 210 (4.6) 288 (6.0) 3.53 3 102 1.43 (1.02-1.98)
TC/GG 577 (12.8) 490 (10.2) 4.18 3 109 2.4 (1.79–3.22)
TC/GA 1,345 (29.8) 1,518 (31.6) 5.00 3 106 1.92 (1.45–2.54)
TC/AA 442 (9.8) 524 (10.9) 1.35 3 103 1.64 (1.21–2.21)
CC/GG 190 (4.2) 188 (3.9) 2.23 3 103 1.71 (1.21–2.40)
CC/GA 332 (7.3) 499 (10.4) 6.50 3 102 1.34 (0.98–1.83)
CC/AA 156 (3.5) 407 (8.5) – 1
ADD/ADD – – 2.81 3 1032 –
The population CAD combined consisted of 4,521 cases and 4,809 controls.
Abbreviations are as follows: padj, p value after adjustment for covariates,
such as age, gender, smoking, BMI, hypertension, DM, Tch, TG, HDL-c, and
LDL-c; ADD, additive model, rs7025417_TT/TC/CC, rs11685424_GG/GA/AA.
656 The American Journal of Human Genetics 93, 652–660, Octoberpg/ml; range, 12–3,807 pg/ml). As shown in Figure 4A,
rs7025417 genotype was significantly associated with
plasma IL-33 levels in subjects with a detectable IL-33 level
(n ¼ 227, R2 ¼ 0.276, p ¼ 1.77 3 1017). The IL-33 protein
levels increasedwith thenumber of risk (T) alleles. The com-
parison between each pair of the three genotypes by the
Mann-Whitney U test confirmed this trend, with p values
that were less than 0.001 (Figure 4B). The results suggested
that rs7025417 could affect the circulation level of IL-33.Discussion
In the present study, we demonstrated that rs7025417 in
IL33 and rs11685424 in IL1RL1 are significantly associated
with CAD in three stages of a case-control association
study based on the GeneID Chinese Han population. The
interaction between the two variants exhibited a much
greater effect than that of a single variant in the association
with CAD, which indicated that these variants could
interact with each other in a biological manner. Given
that the two variants were located within the gene pro-
moter regions, we assessed whether these variants could
influence gene expression by using reporter gene analysis
and found that they did. In addition, rs7025417 genotype
affected the level of circulating IL-33, which indicates that
rs7025417 might influence the development of CAD by
regulating the expression of IL33.
IL-33, a cytokine that belongs to the IL-1 family, has
been shown to be expressed in the nucleus of human
vascular endothelial cells of most healthy tissues and
tumor tissues, as well as epithelial cells exposed to the3, 2013
Figure 2. Comparison between OR Values
(A) OR values with a 95% confidence interval (95% CI) of the combination types under the genotypic model.
(B) The comparison of the OR values with a 95% confidence interval (95% CI) between the combination type ‘‘TT/GG’’ and the geno-
typic models of single variants.
ADD, additive model, rs7025417_TT/TC/CC, rs11685424_GG/GA/AA; DOM, dominant model, rs7025417_TTþTC/CC,
rs11685424_GGþGA/AA; REC, recessive model, rs7025417_TT/TCþCC, rs11685424_GG/GAþAA.external environment and fibroblasts of lymphoid
tissues;36 however, of all the blood cell types, only acti-
vated dendritic cells and activated macrophages express
IL-33 at low levels.37 IL-1RL1, previously known as the
only receptor for the cytokine of IL-33, has two main pro-
tein forms: membrane-bound ST2L and soluble ST2 (sST2).
It has been demonstrated in vitro that IL-33 can activate
many immune cells by binding to ST2L-IL-1RL1 on the
surface of many cells, including Th2 cells, mast cells, baso-
phils, eosinophils, and natural killer cells.36,38–42 In vivo,
the administration of IL-33 can influence multiple inflam-
matory-immune diseases, such as arthritis, asthma, and
inflammatory bowel disease.43–45 This important evidence,
demonstrating the involvement of the IL-33-ST2L
pathway in the immune-inflammatory system, indicated
that this pathway could also have important effects in
the development of atherosclerosis and CAD.
Studies that have addressed the role of the IL-33-ST2L
pathway in atherosclerosis and CAD have yielded conflict-
ing results. Animal studies have indicated that the IL-33-
ST2L pathway reduces macrophage foam cell formation46
and inhibits the development of atherosclerosis in apoli-
poprotein E-deficient (APOE/) mice.25 However, otherFigure 3. The Reporter Gene Analysis
The luciferase activity was tested by means of cellular extracts.
p values less than 0.005 indicate that the difference was statisti-
cally significant between the plasmids. Mean5 SD of the relative
luciferase activity is shown.
The Americstudies have reported that the IL-33-ST2L pathway pro-
motes angiogenesis and vascular leakage and induces
adhesion molecule and proinflammatory cytokine expres-
sion in human endothelial cells,47–49 suggesting that the
IL-33-ST2L pathway enhances the development of CAD
by inducing the activation and injury of the coronary
artery endothelium. To our knowledge, there have been
few genetic or epidemiological studies on the association
between the IL-33-ST2L pathway and CAD. Though
Tsapaki et al. investigated the association between the
distal promoter variants in IL1RL1 and CAD with small
sample size, their significant results indicated that the
IL-33-ST2L pathway might genetically associate with
CAD.50 In the present study, with a large discovery sample
size with sufficient statistical power, we detected that two
tag SNPs in the two genes analyzed (rs7025417 in IL33
and rs11685424 in IL1RL1) were significantly associated
with CAD not only in the subgroup of anatomical disease
(severe coronary stenosis) but also in the subgroup of clin-
ical disease (myocardial infarction or revascularization).
Furthermore, additional functional studies using reporter
gene and circulation level analysis suggested that the
rs7025417 genotype affects the level of circulating IL-33,
which indicates that rs7025417 might influence the devel-
opment of CAD by regulating the expression of IL33. These
results are in agreement with the above in vitro studies
with human endothelial cells, suggesting that the IL-33-
ST2L pathway enhances the development of CAD.
The conflicting results about the role of the IL-33-ST2L
pathway in the development of atherosclerosis and CAD
can be explained as follows. First, evidence provided by
Demyanets et al.,47 Choi et al.,48 and Aoki et al.49 sug-
gested that the IL-33-ST2L pathway could contribute to
the early events of atherosclerosis development via activa-
tion and injury of the coronary artery endothelium. Miller
et al.,25 in contrast, obtained results based on a model in
which atherosclerosis had already developed. Second,
given that the contradictory findings were obtained froman Journal of Human Genetics 93, 652–660, October 3, 2013 657
Figure 4. Circulation Level Analysis of IL-33
(A) Association analysis between the circulation levels of IL-33 and rs7025417 genotype in a linear regression model.
(B) The comparison between every pair of the three genotypes, via theMann-Whitney U test. Special symbols (asterisk or circle) mark the
outliers of the values in different genotypes. A broken line indicates the median value of 233.67 pg/ml for IL-33 in the detectable CAD
individuals.experiments that used different species, IL-33 could func-
tion differently in human and in mouse tissues. The
present study was performed with human cells, producing
results that were consistent with those of the human
studies described above. The influence of genetic variants
on human diseases commences before the occurrence of
the diseases and can begin as early as birth.
In 2006, Kabesch et al. reported that individual SNPs
might interact with each other in a biological way if
their interaction resulted in a more than multiplicative
effect.51 In 2011, Demyanets et al. observed that endothe-
lial cells express both IL-33 and ST2L in the nucleus and
that the mRNA expression of these molecules is signifi-
cantly correlated in the carotid atherosclerotic tissue,47
suggesting that the crosstalk of IL-33 and ST2L-IL-1RL1
significantly enhances the risk of atherosclerosis. In the
present study, we determined that the OR values for the
combination types of the two SNPs were much higher
than the values for a single one in the associations with
CAD (Table 3 and Figure 2). Therefore, we speculated
that the two SNPs might interact each other in a biological
way, which might influence the development of CAD by
regulating the expression of their genes.
There are some limitations to our study. First, although
we performed a three-stage population study, a larger
sample size in different populations is required to replicate
the association results. Second, although the reporter gene
analysis and the circulation study suggested that the two
promoter variants might regulate the gene expression, a
thorough analysis of the loci represented by the two
variants is necessary to detect the causal variants that
have much larger effect sizes.
In conclusion, this study demonstrated that the two pro-
moter SNPs rs7025417 in IL33 and rs11685424 in IL1RL1
are significantly associated with CAD. This finding implies
that the IL-33-ST2L pathway may strongly influence the658 The American Journal of Human Genetics 93, 652–660, Octoberdevelopment of CAD, highlighting the IL-33-ST2L
pathway as a valuable target for the prevention and
treatment of CAD.Supplemental Data
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